Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | LSS | P48449 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | CHKA | P35790 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2196021 | 0.91 | KDM4E (0.36) | PYCR1PDE2AKDM4EGAASMN1; SMN2 | |
| SCHEMBL2194557 | 0.90 | PYCR1 (0.41) | PYCR1PDE2AKDM4ELMNAGAA | |
| SCHEMBL2197110 | 0.87 | PYCR1 (0.33) | PYCR1LSS | |
| SCHEMBL2195738 | 0.87 | OPRL1 (0.40) | PYCR1PDE2AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL2197087 | 0.87 | MAPT (0.43) | PYCR1KDM4EGAASMN1; SMN2NPSR1 | |
| SCHEMBL2193860 | 0.87 | KDM4E (0.36) | PYCR1KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL2193845 | 0.87 | POLB (0.39) | KDM4ELMNAGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL2197400 | 0.86 | ALDH1A1 (0.33) | PYCR1ALDH1A1 | |
| SCHEMBL2195824 | 0.86 | PYCR1 (0.36) | PYCR1PDE2AKDM4ELMNAGAA | |
| SCHEMBL15085514 | 0.86 | SLC6A2 (0.35) | PYCR1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980875-B2 | Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-03-17 | — | — | US | claimed |
| US-20130338128-A1 | PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-12-19 | — | — | US | claimed |
| US-8481522-B2 | Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-07-09 | — | — | US | claimed |
| US-20110172199-A1 | PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-07-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338128-A1 | PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SCO2, C3AR1, IDH1 | PYCR1 75/4885PDE2A 4198/4885KDM4E 4803/4885 |
| US-20110172199-A1 | PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SCO2, C3AR1, IDH1 | PYCR1 75/4885PDE2A 4198/4885KDM4E 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.